



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## Abrocitinib

Item No. 34869

**CAS Registry No.:** 1622902-68-4  
**Formal Name:** N-[cis-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclobutyl]-1-propanesulfonamide  
**Synonym:** PF-04965842  
**MF:** C<sub>14</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S  
**FW:** 323.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 288 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Abrocitinib is supplied as a solid. A stock solution may be made by dissolving the abrocitinib in the solvent of choice, which should be purged with an inert gas. Abrocitinib is soluble in DMSO.

### Description

Abrocitinib is a JAK1 inhibitor (IC<sub>50</sub> = 0.029 μM).<sup>1</sup> It is selective for JAK1 over JAK2, JAK3, and TYK2 (IC<sub>50</sub>s = 0.803, >10, and 1.253 μM, respectively) and a panel of 40 kinases at 1 μM. Abrocitinib inhibits IFN-α-, IL-21-, or IL-27-induced phosphorylation of STAT3 (IC<sub>50</sub>s = 0.189, 0.511, and 0.271 μM, respectively) and IFN-γ-induced phosphorylation of STAT1 (IC<sub>50</sub> = 0.163 μM) in isolated human whole blood. It reduces paw edema in a rat model of adjuvant-induced arthritis when administered at doses of 1, 5, and 15 mg/kg. Formulations containing abrocitinib have been used in the treatment of atopic dermatitis.

### Reference

1. Vazquez, M.L., Kaila, N., Strohbach, J.W., *et al.* Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases. *J. Med. Chem.* **61**(3), 1130-1152 (2018).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM